Look I have the feeling that Invion 103 has just lacked some love. The big more immediate prize is with our respiratory drugs. Yesterdays announcement IMO was quite inadequate. It was the first bit of news since September 8 last year where the company said they 'look forward to leveraging this understanding into the final cohorts of the study, which include significantly higher dosages in patients with more severe disease'. What has happened to all the talk around Lupus nephritis? These patients with class 1 and 2 kidney disease were recruited??? The drug suppressed nephritis in mice studies. 2 year trial for 28 patients, 2 announcements...... a real shame, this novel drug needs to get to market.
Ugly step sister
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(20.0%) |
Mkt cap ! $25.69M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $5.78K | 1.445M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 12797949 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 7472779 | 27 |
View Market Depth
| Last trade - 14.20pm 28/06/2024 (20 minute delay) ? |
| IVX (ASX) Chart |